SCHEMBL517527

SCHEMBL517527

COc1cc([PH]2(O)CCC(N(C(=O)O)C(C)C)CC2)ccc1N

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.37
HSD11B1 P28845 3/20 0.36
CYP3A4 P08684 3/20 0.34
GAA P10253 2/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
HTR4 Q13639 3/20 0.34
TSHR P16473 3/20 0.34
MAPT P10636 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
CHRM4 P08173 1/20 0.33
CHRM5 P08912 1/20 0.33
ADRA2C P18825 1/20 0.33
CHRM3 P20309 1/20 0.33
HTR1D P28221 1/20 0.33
ADRA1B P35368 1/20 0.33
HTR2B P41595 1/20 0.33
HTR3A P46098 1/20 0.33
ALDH1A1 P00352 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL517528 0.76 TP53 (0.35) TP53HSD11B1CYP3A4GAACYP1A2
SCHEMBL517526 0.76 TP53 (0.37) TP53HSD11B1CYP3A4GAACYP1A2
SCHEMBL11900226 0.66 HTR4 (0.41) CYP3A4GAAHTR4TSHRCHRM4
SCHEMBL24059578 0.65 ALDH1A1 (0.36) HSD11B1CYP3A4HTR4TSHRCHRM4
SCHEMBL1491821 0.64 HTR4 (0.44) CYP3A4CYP1A2CYP2C9HTR4ADRA2C
SCHEMBL5260286 0.60 TRPM8 (0.48) CYP3A4GAACYP1A2CYP2C9CYP2C19
SCHEMBL21847022 0.60 LGMN (0.42) HSD11B1HTR4MAPTALDH1A1
SCHEMBL3315336 0.60 AKR1C3 (0.56) CYP3A4CYP1A2CYP2C19TSHRNPSR1
SCHEMBL4667302 0.60 ALDH1A1 (0.49) CYP3A4CYP1A2CYP2C19TSHRMAPT
SCHEMBL15651002 0.60 ALDH1A1 (0.45) CYP3A4CYP1A2CYP2C9CYP2C19TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2601186-A2 4-(1H-INDOL-3-YL)-PYRIMIDINES AS ALK INHIBITORS AstraZeneca AB (SE) 2013-06-12 EP disclosed
US-8461170-B2 Chemical compounds ASTRAZENECA AB (SE) 2013-06-11 US disclosed
WO-2012017239-A2 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2012-02-09 WO disclosed
US-20120028924-A1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2012-02-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120028924-A1 CHEMICAL COMPOUNDS ALK, BRAF, ABL1 TP53 159/4885HSD11B1 976/4885CYP3A4 600/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.